Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $56.1 million.

  • Axsome Therapeutics' Change in Accured Expenses rose 919.11% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 144.85%. This contributed to the annual value of $56.1 million for FY2024, which is 53.81% up from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Change in Accured Expenses is $56.1 million, which was up 53.81% from $36.5 million recorded in FY2023.
  • Axsome Therapeutics' Change in Accured Expenses' 5-year high stood at $56.1 million during FY2024, with a 5-year trough of -$2.2 million in FY2020.
  • Over the past 3 years, Axsome Therapeutics' median Change in Accured Expenses value was $43.9 million (recorded in 2022), while the average stood at $45.5 million.
  • In the last 5 years, Axsome Therapeutics' Change in Accured Expenses tumbled by 131.47% in 2020 and then surged by 7,446.91% in 2022.
  • Over the past 5 years, Axsome Therapeutics' Change in Accured Expenses (Yearly) stood at -$2.2 million in 2020, then surged by 126.03% to $582,000 in 2021, then surged by 7,446.91% to $43.9 million in 2022, then decreased by 17.01% to $36.5 million in 2023, then skyrocketed by 53.81% to $56.1 million in 2024.